Atterocor, Inc. has initiated a Phase I trial of ATR-101 for the treatment of adrenocortical carcinoma (ACC). ATR-101 is a novel, oral drug candidate that has shown selective effects on cells derived from the adrenal cortex in a variety of preclinical studies. Atterocor’s first-in-human study is designed to establish the safety and tolerability of ATR-101 in patients with advanced ACC, whose disease has progressed on standard therapy. Tumor and biomarker responses will also be observed. The Pha...